Piper Sandler Maintains Overweight on Syros Pharmaceuticals, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff maintains an Overweight rating on Syros Pharmaceuticals (NASDAQ:SYRS) but lowers the price target from $11 to $7.
October 03, 2023 | 7:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has maintained an Overweight rating on Syros Pharmaceuticals but lowered the price target from $11 to $7.
The lowering of the price target by Piper Sandler from $11 to $7 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100